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Abstract 
Background: Hepatitis viruses are common cause of viral hepatitis, it has a varied distribution among 
people, it has more than five common types: Hepatitis A, B, C, D, E. Hepatitis B,C,&D occurred by 
parenteral route. Hepatitis E occurres specially in pregnant women by feco-oral route. Interleukin-4 (IL-4) 
protect human hepatocellular cell line from apoptosis and suppresses the expression and replication of 
hepatitis B virus. Exposure to HCV antigens increased L-10 production by polymorphonuclear cells and T 
cells. 
Aim of study: To monitor the significance of IL-4 and IL-10 among patients with chronic HBV and HCV, 
to find the frequency of confirmed hepatitis virus in Babylon City and to compare between their 
percentages and possible cause of transmission and method to prevent it 
Materials and Methods: A total number of 18 patients for each group of hepatitis B and C were taken to 
estimate of IL-4 and IL-10 which compared with 14 apparently healthy control group in Central Public 
Health Lab/ Babylon during the period from January-June, 2008.  
Results: The results showed highly significant decrease in IL-4 in both groups in comparison to control 
group while IL-10 showed highly significant increase in both group in comparison to control group. 
Conclusions: Immune factors are essential in the consequence of chronic HBV and HCV infection. Serum 
IL4 might be used as a laboratory parameter to indirectly assess liver damage instead of invasive 
histopathological examination. IL-10 might influence HCV and HBV infections susceptibility due to its 
anti-inflammatory action. IgG4 might further aggravate the disease course of HBV and HCV infection 
caused by IL-10. 
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Introduction 
      Viral hepatitis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) 
constitutes a major economic and public health problem in the world due to high rate of 
morbidity, mortality and development of chronic carrier state(1-3). Hepatitis B virus 
(HBV )is the smallest human DNA virus and had a very compact genome, belongs to the 
family Hepadnaviridae, which involves a group of highly species – specific DNA virus 
(4). HCV is an RNA virus with lipid coat like  flaviviridae family. Chronic HBV was 
usually defined as detectable hepatitis B surface antigen (HBs Ag) for a period of six 
months or more (5). Researches showed that the world prevalence of HBs Ag carriers 
was from 0.1% till 20% with high ratio in tropical countries (6&7). The chronic form of 
hepatitis B was characterized by several phases, including immunotolerance, long-lasting 
ARTICLE INFO 
Submission date: 5 / 5/ 2019 
Acceptance date: 24/ 7 /2019 
Publication date: 1 /11 /2019 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (5): 2019 
 
55 
 
hepatitis with positive or negative HBe Ag, as well as the chronic disease carrier(8-10). 
HCV had been shown to be an etiologic agent responsible for chronic liver disease, with 
eventual development of cirrhosis and hepatocellular carcinoma. While the immunologic 
mechanisms in chronic HCV infection have not been clearly defined, it is believed that 
cytokines were involved (11). This complex clinical framework was the result of the 
interaction of factors inherent to the host and the virus, as well as environmental 
conditions, but is related primarily to the age and immunological status of the infected  
person (12-15). The understanding of the complex virus–host interaction which resulted 
in a variety of clinical manifestations, necessarily required a good working knowledge of 
the immunopathogenesis of the disease and the importance of the immunological profile 
of the host and its cytokine secretion pattern(16&17). In addition, the function of T helper 
type 1 (Th1) and Th2 cytokines were wide-ranging and include regulatory signals for 
activation, growth and differentiation of cytotoxic lymphocytes, macrophages, natural 
killer cells and granulocytes. Previous studies have inspected the role of cytokines, 
including tumor necrosis factor, IL1, IL2,  IFN- α and IFN-γ, in hepatitis B and HIV. 
However, there had been little studies that specifically analyzed the levels of 
immunoregulatory cytokines in these chronic infections (18). However, in the context of 
an inflammatory response against a virus, cytokines might also clue to liver damage (19) 
and led to changes in liver enzymes e.g. ALT which is mostly concentrated in liver and 
released into the bloodstream as the result of liver injury. It, therefore, serves as a fairly 
specific indicator of liver status (20). For this purpose, this study aimed to find the 
frequency of confirmed hepatitis virus in Babylon, monitor the significance of IL-4 and 
IL-10 among chronic hepatitis patients and to compare between their percentages and 
possible cause of transmission and method to prevent it. 
 
Patients and Methods 
Patients and control : 
      A total of (18) patients with HCV and (18) patients also with HBV infection who 
consulted Central public Health Laboratory during the period from January - June ,2008 
were enrolled in this study. In addition (14) individuals who were apparently healthy and 
consulted Central Public Laboratory for other purposes were included as a control group. 
Blood aspiration: 
      A volume of 7  ml venous blood sample was taken from all patients and control 
individuals for detection of HBs antigen and anti-HCV antibody to confirm the ELISA 
results obtained from Central Public Health Laboratory. Blood sample was divided into 
two volume, one used for Polymerase chain reaction technique and the second was used 
for ELISA technique. The ELISA samples were centrifuged and sera were separated until 
time of testing. 
Method:  
The ELISA technique: 
       It was used for testing the samples by a sandwich principle. The initial diagnosis was 
a positive anti HCV antibody and HBS antigen from data supplied from Central Public 
Health Laboratory (Biotest United Biomedical Inc. USA). Serum anti-HCV antibody and 
HBS antigen were repeated again by third-generation ELISA (CTK-Biotech, USA) to 
confirm the serological diagnosis of Central Health Laboratory. IL-4 (Biosource, USA) 
and IL-10  (Marseille / France) were also assessed by ELISA technique.   
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Polymerase chain reaction technique: 
Detection of HCV RNA 
      HCV RNA preparation and cDNA synthesis had done according to (21). Recycling of 
the extracted RNA was done as a template and amplified via RT-PCR with primers that 
were precise with 5UTR of HCV (22&23). PCR product were re-amplified by the same 
cyclic program, and for each pair of primer, negative controls that lacking template were 
included. If a control was positive, all PCR products were considered contaminated 
products and then discarded. Electrophoresis with 2.0% agarose gel of amplified cDNA 
was done to detect the amplicon of PCR product.  
Detection of HCV genotypes  
      HCV genotypes were done by core region amplification with primers that were 
genotype specific  (genotypes 1, 2, 3 and 4 )(24&25). Fragment of HCV core gene (272 
bp) was amplified with universal primers from HCV cDNA. A portion of the product was 
then amplified through universal sense primers by PCR and a mixture of five antisense 
primers gathered from HCV core gene sequences specific for HCV genotypes (1, 2, 3 and 
4 )(26&27).The four genotypes were differentiated from each other by PCR products 
size: (123,  211, 240 and 188 bp) for genotype 1, 2,3 and 4 respectively. 
Radial immunodiffusion (RID): (RID)(Fitzgerald industries Int, USA). 
       RID (Mancini) method was the diagnostic method that used to determine IgG4 
subclasses in agar plates (ready for use), holding the specific anti-IgG4 subclass 
antibodies. Test samples, control and standard sera were prepared to be added to the 
plates. After incubation for 48-72 hours at room temperature, the immunoprecipitation 
rings diameters were measured. The IgG4 subclass levels in the test samples was 
quantified by calibration curve procedure where concentrations of the standards and ring 
diameters were plotted and the values of tested samples were determined by 
interpolation. 
 
Statistical methods 
          All data were presented as means and the deviations were presented as standard 
deviation, and to test the significance in means of different quantitative data, independent 
sample t- test of significance was applied. Correlation analysis was done in SPSS version 
15.0. P value below 0.05 was accepted as statistically significant value. 
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Results 
 
Figure (1): Frequency of confirmed HCV infection(by PCR) among seropositive 
HCV patients. This  showed that out of 29 patients with positive anti HCV infection, 
only 18 case ( 62.06%) had positive HCV RNA confirmed by molecular technique 
(PCR). 
 
Table (1): Frequency of asymptomatic and symptomatic HCV and HBV infection This 
showed that 7 out 18( 38.89%) HCV infections were asymptomatic and the remaining 11 
out 18 (61.11%) were symptomatic HCV infections while 6 out of 18 (33.33%) were 
asymptomatic and the remaining 12 out of 18 (66.67%) were symptomatic HBV 
infections. 
Chronic infection No % 
HCV 
Total(18 ) 
Asymptomatic 7 38.89 
Symptomatic 11 61.11 
HBV 
Total(18 ) 
Asymptomatic 6 33.33 
Symptomatic 12 66.67 
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Table (2): Mean levels of IL-4 among patients with HBV and HCV infections.  This 
showed that IL4 was significant decrease in asymptomatic chronic HBV and HCV in 
comparison to control (P value < 0.05) while it was significantly decreased in patients 
with symptomatic HCV and chronic HBV infection  in comparison to control group (P 
value < 0.001). 
 
Infection 
IL-4 Control  
P value Means SD Means SD 
Patients with HCV 
chronic hepatitis 
Asymptomatic  5.46 1.02  12.34 1.38 < 0.05 
Symptomatic  1.56 0.76 12.34 1.38 < 0.001 
Patients with HBS 
chronic hepatitis 
Asymptomatic infection   4.59 0.98 12.34 1.38 < 0.05 
Symptomatic infection   1.11 0.43 12.34 1.38 < 0.001 
 
Table (3): Mean levels of IL10 among patients with  HBV and HCV infections. This 
showed that IL10 was significant increase in asymptomatic chronic HBV and HCV in 
comparison to control group (P value<0.05) and highly significant increases in 
symptomatic chronic HCV and HBV infection in comparison to control group (P value 
<0.05). 
 
Infection 
IL-10 Control   
P value Means SD Means SD 
Patients with 
HBS 
chronic hepatitis 
Asymptomatic infection  44.95 5.43 6.2 0.92 < 0.05 
Symptomatic infection 115.12 414.38 6.2 0.92 < 0.001 
Patients with 
HCV chronic 
hepatitis 
Asymptomatic infection  52.36 7.84 6.2 0.92 < 0.05 
Symptomatic infection 124.50 16.13 6.2 0.92 < 0.001 
 
 
Table (4 ): the frequency of HCV according to its genotyping 
 
HCV 
Genotype by 
Real time 
PCR 
technique 
Studied groups HCV positive HCV 
negative 
Total 
 
HCV 
RNA 
positive 
1a 6 33.33 0 0 6 33.33 
1b 2 11.11 0 0 2 11.11 
4 7 38.89 0 0 7 38.89 
Mixed(1a+4) 2 11.11 0 0 2 11.11 
Mixed (1b+4) 1 5.56 0 0 1 5.56 
Total 18 100 0 0 18 100 
Control Any or all type 0 0 14 100 14 100 
 
 
 
 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (5): 2019 
 
59 
 
 
 
Figure (2): the mean IgG4 level in asymptomatic and symptomatic HCV and HBV 
infections 
 
Discussion 
           Carey had stated that ELISA was accurate serological marker for diagnosis of 
HCV infections but it still gave false positive and false negative results(28). So the wide 
discrepancy could be attributed to the fact that HCV might be founded in peripheral 
blood mononuclear cells and not in serum or plasma to be detected serologically (29) in 
addition to that the spontaneous viral clearance might occur in twenty percent of 
individual exposed to the virus (30). 
         As it was shown in this study that the IL4 (table 2) was decreased  and IL10 (table 
3) was increased in symptomatic than in asymptomatic chronic HBV and HCV infection, 
so these might lead to inhibition of activated macrophages and cell-mediated immunity 
(Th1) and subsequently lead to potent down-regulation of IFN-γ by Th1 cells and inhibits 
the immune response to viral infection that finally resulted in imbalance in Th1 and Th2 
cytokines to be concerned as an significant part in the pathogenesis of chronic hepatitis 
(31)with subsequent change in liver enzymes and aggravating the disease symptoms (32).  
This was consistent with (31). This might be due to type of intrahepatic infiltrating T 
cells which could be Th1 cells that were unable to secrete IL-4 (33), so this might reflect 
disease severity. It was noteworthy that there was a correlation between T cell response 
and a clinically benign course of the liver diseases and eradication of the virus. As the 
assessment parameter nowadays was the histopathological examination which was 
invasive laboratory technique and as there was significant reduction of IL-4 occurred in 
symptomatic infections, so this parameter might indirectly reflect the pathological picture 
in these diseases and might be used as a laboratory parameter to indirectly assess liver 
damage by serum examination instead of histopathological examination or when the later 
technique was indicated to be repeated in future for many times to  assess treatment 
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efficacy. Further studies would be recommended to confirm the true histopathological 
status in relation to serum levels of these two parameter together with large sample size. 
As Th2 was anticipated to be down regulated in this study through a decrease production 
of IL4  (table 2), so the highly significant production of IL10 may be from cells other 
than Th2 e.g.  numerous cell forms in liver, containing hepatocytes, hepatic stellate cells, 
sinusoidal endothelial cells, Kupffer cells and liver-associated lymphocytes which had 
anti-inflammatory action through the inhibition of IL-6, IL-8, IL-12, and TNF-α synthesis 
by activated macrophage and interferon-γ by T cells (35). In addition to that  inhibition of 
activated macrophages, which played a crucial role in the homeostatic control of innate 
immune reactions and cell-mediated immunity might lead to potent down-regulation of 
the production of IFN-γ by Th1 cells and inhibition of the immune response to viral 
infection (36), so it might  influence HCV and HBV infection susceptibility(37). The 
significant reduction in IL10 production in those patients with asymptomatic HBV and 
HCV infection in comparison to symptomatic HBV and HCV might be responsible for 
reduction of symptoms and a better enhancement of immune response against virus, so 
this might favor a forceful CD4+ and CD8+ T-cell response with a tendency to rise in 
Th1 cytokine profile and this seem to be accountable for recovery from these chronic  
infections(38). On the other hand, patients who progress to symptomatic chronic 
infection and showed a prime Th2 response could down regulates the Th1 response and 
therefore favors persistent HCV infection. It had been reported that the IL-10 gene 
promoter polymorphisms might occurred during the natural course of HCV infection 
(39). It had been shown that inter-individual difference in IL-10 production was 
determined genetically(40). Therefore, there is a prerequisite for larger studies to propose 
any part of cytokine gene polymorphisms in HCV outcome and in order to orient 
molecular epidemiological research of IL-10 polymorphisms sites and HCV infection 
susceptibility in the future. 
        It is now well documented that therapeutic outcome of antiviral treatment is 
influenced by the virus genotype as  prior knowledge of the genotype before therapy had 
become an important aspect of therapeutic strategy, because of its predictive value in 
terms of the response to antiviral therapy. It  also provides information as to strain 
variation and potential association with disease severity. In addition, it is of 
epidemiologic value because it sheds light on whether prevalent HCV strains are similar 
to that endemic in a certain region, such as in the Middle East( 41 ). 
Table( 4 ): showed that 7 out of 18 ( 38.89 %) had HCV genotype 4 ,hence it was 
considered the commonest genotype, followed by HCV genotype 1a (33.33 %), HCV 
genotype 1b (11.11%), mixed HCV genotype (1a+4)(11.11%) and mixed HCV genotype 
(1b+4) (5.56%). The mixed infections that had been noted in this study could be 
attributed to mutations in the viral genome or co-infection of both together (42).Five out 
of 6 (83.33%) of patients with HCV genotype 1a give history of using hemodialysis , so it 
was more likely to disseminate in hemodialysis. This was consistent with (43). Infection 
with two or more different HCV genotypes has been observed in hemodialysis patients 
(44). Grouping of anti-HCV positive patients in dialysis units might thus increase the risk 
of acquiring multiple HCV strains. So using PCR technique for grouping of anti-HCV 
positive patients in relation to HCV genotype might be helpful to prevent HCV genotypes 
co-infection. The pattern of HCV genotypes encountered in this study was similar to 
those reported from other countries such as Saudi Arabia and Lebanon, where genotype 4 
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is the most prevalent (45&46). However, this should not be general to all HCV cases 
widespread in Iraq because of small size sample. Analysis should be done with a larger 
population, including hemodialysis patients and blood donors, to determine the prevalent 
HCV genotype (45). HCV genotype 1a is the most prevalent genotype in Jordanian 
patients' blood donors and in haemodialysis patients of some Middle Eastern countries 
including Lebanon, Turkey, Cyprus and Syria. In contrast, HCV genotype 4 was the most 
prevalent genotype in other Middle Eastern countries including Saudi Arabia, Egypt, 
Yemen and Bahrain (47).  
           Fig. (2) showed that there was significantly high IgG4 level in symptomatic 
infection of both types (P value > 0.05). This probably due to increase in IL-10 that had 
been found in this study as excessive production of this anti-inflammatory cytokines 
would triggers an overwhelming expansion of IgG4-producing plasma cells (48&49).  It 
had been shown previously that the serum IgG4 was positivily linked with the increase in 
peripheral memory T regulatory cells(49) and the up regulation of  IL-10 in livers of the 
patients with IgG4-sclerosing cholangitis was by prominent infiltration of T regulatory 
cells, so this  outcomes suggested that IgG4 did not act as a pathogenic factor, but as an 
anti-inflammatory element that might worsen the course of disease due to the anti-
inflammatory action of IL-10.  Based on genetic experiences, acquired and innate 
immunity, regulatory T or B cells, Th2-dominant immune status, and complement 
activation through a classical pathway might be complicated in the progress of IgG4-
related disease. Although the role of IgG4 remains unclear in IgG4-related disease, IgG4-
production was  up regulated by IL-10  from T regulatory cells and by B cell activating 
factor from monocytes/basophils with toll-like receptors/nucleotide-binding 
oligomerization domain-like receptors stimulation(50). Further studies are necessary to 
clarify the pathogenic mechanism of IgG4. 
  
Conclusions 
It could be concluded that host immune elements are significant in the consequence 
of HBV and HCV infection. Serum IL4 might be used as a laboratory parameter to 
indirectly assess liver damage instead of invasive histopathological examination. IL-10 
might influence HCV and HBV infections susceptibility due to its anti-inflammatory 
action. IgG4 might further aggravate the disease course caused by IL-10. 
 
Recommendations 
1-Further study are recommended to study IL4 and IL10 gene polymorphisms as they 
may potentially lead to spontaneous clearance of viral hepatitis infection. 
2- Further study with large sample size are indicated. 
 
 
 
 
 
 
 
 
 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (5): 2019 
 
62 
 
Conflict of Interests.  
There are non-conflicts of interest . 
 
References 
1-Alter, M. J. ; Margolis, H. S.; Krawezynski , K. et al (1992). The natural history of 
community acquired hepatitis C in US. N Engl. Med; 327:1889-1905. 
2-WHO. Global surveillance and control of hepatitis C. (1999). Report of a WHO 
consultation organized in collaboration with viral hepatitis prevention board. J viral 
Hepat ; 6: 35-67. 
3-Wong, J. P.; Mc~uillan, G. M.; Mchutchison, J. G. et al.( 2000). Estimating future 
hepatitis C morbidity, mortality and cost in the United State. Am J Public Health 
;90:1562-1569. 
4-Wang, G. & Seeger, C. (2003). mechanism for reverse transcription in hepatitis B 
viruses". J.virol;67:6507-6512. 
5-Hyams, K.C.(1995). Risks of chronicity following acute hepatitis B virus infection. A 
review. Clin. Infect. Dis; 20(4):992-1000. 
6- Friss, R. & Seller, T. A. (2004). Epidemiology for public health practice. Volume 
Chapter 12. Jones and Bartlett Publishers, London. 
7-Kyi, K. P.; Aye, M.; Oo, K.M.; Htun, M.; Oo, S.S.; Lwin, K.O. & Win, K.M. (2002). 
Prevalence of Hepatitis C in Healthy Population and Patients with Liver Ailments in 
Myanmar. Regional Health Forum WHO South-East Asia Region;6(1). 
8-  Pungpapong, S.; Kim, R. W. & Poterucha, J. J. (2007). Natural history of hepatitis B 
virus infection: an update for clinicians. Mayo Clin Proc; 82: 967–75. 
 9-Fattovich, G.; Bortolotti, F. & Donato, F. (2008). Natural history of chronic hepatitis 
B: special emphasis on disease progression and prognostic factors. J Hepatol ;48: 
335–52.  
10-McMahon, B. J. (2008). Natural history of chronic hepatitis B – clinical implications. 
Medscape J Med; 10(4): 91.  
11-Cacciarelli, T. V.; Martinez, O. M. ; Gish, R. G. ; Vilianueva, J. C. & Krams, S. M. 
(1996). Immunoregulatory cytokine in chronic hepatitis C virus infection: Pre- and 
post-treatment with interferon alfa. Hepatology ; 24(1): 6-9. 
12- McMahon, B. J. (2008). The influence of hepatitis B virus genotype and subgenotype 
on the natural history of chronic hepatitis B. Hepatol Int.;3(2):334-42. 
13- Feld, J.J. & Heathcote, J. (2006). Hepatitis B e antigen-positive chronic Hepatitis B: 
natural history and treatment. Semin Liver Dis ; 26: 116–29. 
14- Lin, C. L. & Kao, J .H.(2008). Hepatitis B viral factors and clinical outcomes of 
chronic hepatitis B. J Biomed Sci ; 15 :137–45.  
15-Wong, G. L. ; Wong, V.W.; Choi, P.C.; Chan, A.W.; Chim, A.M.; Yiu, K.K. et al. 
(2008). Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis 
B. Gut; 58: 111–7. 
16-Bertoletti, A. & Gehring, A.J.(2006). The immune response during hepatitis B virus 
infection. J Gen Virol;87:1439–49. 
17-Baumert, T. F.; Thimme, R. & Weizscker, F. (2007). Pathogenesis of hepatitis B virus 
infection. World J Gastroenterol ; 13:82–90. 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (5): 2019 
 
63 
 
18-Spits, H.; Yssel, H.; Paliard, X.; Kastelein, R.; Figdor, C. & de Vries, J.E.(1988). 1L-4 
inhibits 1L-12 mediated induction of human lymphokine-activated killer cells, but 
not generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte 
cultures. J. Immunol.;141:29-36. 
19-Koziel, M. J.( 2003). Cytokines in viral hepatitis. Seminars in Liver Disease ; 19: 157-
169.   
20-Lee, Y. S.; Yoon, S.K.; Chung, E.S.; Bae, S.H.; Choi, J.Y.; Han, J.Y.; et al(2001). The 
Relationship of Histologic Activity to Serum ALT, HCV genotype and HCV RNA 
titers in Chronic Hepatitis C. J Korean Med Sci.;16:585–91. 
21-Hermida, M.; Ferreiro, M.C.; Barral, S.; Laredo, R.; Castro, A. and Diz, D.P.(2002). 
Detection of HCV RNA in Saliva of patients with hepatitis C virus infection by using 
a highly sensitive test. J. Virol. Methods.,101 (1-2): 29-35. 
22-Bukh, J.; Purcell, R. H. & Miller, R.H. (1992). Importance of primer selection for the 
detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc. 
Natl. Acad. Sci., U.S.A.; 89 (1): 187-191.  
23-Ohno, O.; Mizokami, M.; Wu , R.R. and et al. (1997). New hepatitis C virus (HCV) 
genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 
3b, 4, 5a and 6a. J. Clin. Microbiol, 35 (1): 201-207. 
24-Song, P.; Duc, D.D.; Hien, B. et al. (1994). Markers of hepatitis C and B virus 
infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam.Clin. 
Diagn. Lab. Immunol, 1 (4): 413-8.  
25- Okamoto, H.; Tokita, H.; Sakamoto, M.et al (1993). Characterization of the genomic 
sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific 
detection. J. Gen. Virol; 74 (11): 2385-2390. 
26-Okamoto, H.; Sugiyama, Y.;Okada, S.  et al (1992). Typing hepatitis C virus by 
polymerase chain reaction with type-specific primers: application to clinical surveys 
and tracing infectious sources. J. Gen. Virol; 73 (3): 673-679.  
27-Song P, Duc DD ;Hien B and et al. (1994). Markers of hepatitis C and B virus 
infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. Clin. 
Diagn. Lab. Immunol, 1 (4): 413-8. 
28-Carey, D.W. (2010). Review: Hepatitis C virus: Prevention, screening and 
interpretation of assays. Cevel.Clin.J.Med.; 77(9): 616-26. 
29-Caudai, C.; Padula, M.G.; Bastianoni, I.; Valensin, D.E.;Shyamala, V.; Han, J.; 
Boggiano, C.A. and Almi, P. (1998). Antibody testing and RT-PCR results in 
hepatitis C virus infection : HCV RNA detection in PBMC of plasma viremia 
negative HCV sero-positivepersons. Infec.; (3): 151-154. 
30- Feldman, M.; Friedman, L. and Brandt, L. (2007). Gastrointestinal and Live disease: 
Pathophysiology, Dignosis, Management. 8th ed. Elsevier. Canada. 
31-Napoli, J.; Bishop, G.A.; McGuinness, P.H.; Painter, D.M. & McCaughan, G. 
W.(1996). Progressive liver injury in chronic hepatitis C infection correlates with 
increased intrahepatic expression of Th1-associated cytokines. Hepatology;24:759–
765. 
32-Moore, K.W.; Waal Malefyt , R.; Coffman, R.L.& O’Garra, A.( 2001). Interleukin-10 
and the interleukin-10 receptor. Annu Rev Immunol.;19:683–765.   
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (5): 2019 
 
64 
 
33- Bertoletti, A.; D'Elios, M.M.; Boni, C.;Durazzo, M. and Missale, G.(1997). Different 
cytokine profiles of intrahepatic T-cells in chronic hepatitis B and hepatitis C virus 
infections. Gastroenterology; 112:193-199. 
34-Kovel, M.J.; Dudley, D. and Afdhal, N.(2002). Hepatitis C virus (HCV) specific 
cytotoxic T lymphocytes recognize epitopes in the core and envelop proteins of 
HCV. J. Virol.; 67: 7522.   
35- D’Andrea, A.; Aste-Amezaga, M.; Valiante, N.M.; Ma, X.; Kubin, M.; Trinchieri, 
G.(1993). Interleukin 10 (IL-10) inhibits human lymphocyte interferon-gamma-
production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in 
accessory cells. J Exp Med.;178:1041–1048.  
36- Moore, K.W., de Waal Malefyt R, Coffman RL, O’Garra A (2001). Interleukin-10 
and the interleukin-10 receptor. Annu Rev Immunol.;19:683–765. 
37- Morgan, T.R.; Lambrecht, R.W.; Bonkovsky, H.L.; Chung, R.T.; Naishadham, D.; 
Sterling, R.K.; Fontana, R.J.; Lee, W.M.; Ghany, M.G.; Wright, E.C.; O'Brien, T.R. 
HALT-C Trial Group(2008). DNA polymorphisms and response to treatment in 
patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol. 2008 
Oct;49(4):548-56. 
38-Koziel, M.J.(2005). Cellular immune responses against hepatitis C virus. Clin Infect 
Dis.; 41(1) : 25–31. 
39- Yee,  L.J.; Tang, J.; Gibson, A.W.; Kimberly, R.; Leeuwen, D.J.; Kaslow, R.A. 
(2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral 
therapy for chronic hepatitis C infection. Hepatology;33:708–712.  
40- Westendorp, R.G.; Langermans, J.A.; Huizinga, T.W. et al.(1997). Genetic influence 
on cytokine production and fatal meningococcal disease. Lancet; 349: 170–173. 
41- Kabir, A.;Alavian, S.M.; Keyvani,H. (2006). Distribution of hepatitis C virus 
genotypes in patients infected by different sources and its correlation with clinical 
and virological parameters: a preliminary study, Comparative Hepatology;5:4.  
42- Silva, L.K.; Parana, R.; Souza, S.P. et al. (2000).Hepatitis C Virus Genotypes in a 
Northeastern Area of Brazil. Am J Trop Med. Hyg.; 62(2), 257–260. 
43-Espírito-Santo, M.P.; Carneiro, M.A.; Reis, N.R. et al.( 2007). Genotyping hepatitis C 
virus from hemodialysis patients in Central Brazil by line probe assay and sequence 
analysis. Brazilian Journal of Medical and Biological Research.; 40: 545-550. 
44- Wang, N.S.; Liao, L.T.& Zhu, Y. J. et al (2000). Follow-up study of hepatitis C virus 
infection in uremic patients on maintenance hemodialysis for 30 months. World J 
Gastroentero.; 6(6): 888-892. 
45- Matar, G.M.; Sharara, H. M.; Abdelnour, G.E. et al.(1996). Genotyping of Hepatitis 
C Virus Isolates from Lebanese Hemodialysis Patients by Reverse Transcription-
PCR and Restriction Fragment Length Polymorphism Analysis of 59 Noncoding 
Regions. Journal Clinical Microbiology.; 34 (10): 2623–2624. 
46- Utama, A.; Budiarto, B.R.; Monasari, D.; Octavia, T.I.; Chandra, I.S.; Gani, R.A.; 
Hasan, I. Sanityoso, A.; Miskad, U.A.; Yusuf, I.; Lesmana, L.A.; Sulaiman, A.& Tai, 
S. (2008). Hepatitis C virus genotype in blood donors and associated liver disease in 
Indonesia. Intervirology. 2008;51(6):410-6  
47-Bdour, S.( 2002). Hepatitis C virus infection in Jordanian haemodialysis units: 
serological diagnosis and genotyping. J Med Microbiol.; 51: 700–704. 
 9102 :)5( .oN ,)72( .loV ,secneicS deilppA dna eruP rof nolybaB fo ytisrevinU fo lanruoJ
 
 56
 
 era snoitcaer enummi yrotaluger dna 2hT .)7002(.la te .K ,adaraH ;.T ,iijuF ;.Y ,neZ-84
 .sitignalohc dna sititaercnap gnisorelcs detaler-4G nibolgonummi ni desaercni
  .6451-8351:54;ygolotapeH
 dna evian gnitalucriC .)8002( .la te .T ,ihcuginaT ;.K ,adihcU ;.H ,ihsoyiM -94
 .sititaercnap enummiotua htiw stneitap ni sllec T yrotaluger hgih52DC+4DC
   .041-331:63;saercnaP
 dna sllec T yrotaluger fo sisylanA .)8002(.la te .H,ihsoyiM ;.K ,adihcU ;.M ,ubayoK -05
 dna sitignalohc gnisorelcs detaler-4GgI fo stneitap gnoma sllec amsalp evitisop-4GgI
 .147-237:54 ;loretneortsaG J .sesaesid revil enummiotua
 
 الخلاصة
شائعة:  ة انواعلها انتشار مختلف في ما بين المرضى ولها خمس: فيروسات التهاب الكبد هي مسببات شائعة للالتهاب الكبد و الخلفية العلمية
كبد تحدث عن طريق الحقن. فايروس التهاب ال D dna C ,B. فايروس التهاب الكبد نوع   ,E ,D ,C ,B ,Aفايروس التهاب الكبد نوع 
ويثبط  يا الكبد من موت الخلايا المبرمجيحمي خلا 4-يحدث خاصة لدى النساء الحوامل عن طريق الجهاز الهضمي. الانترلوكين   Eنوع 
يق عن طر  01-يزيد انتاج الانترلوكين  C . التعرض الى مستضدات فايروس التهاب الكبد نوع Bمن تكاثر فايروس التهاب الكبد نوع 
 الخلايا الحبيبية متعددة الاشكال و الخلايا التائية.
 Cنوع  و Bبين المرضى الذين يعانون من التهاب الكبد الفايروسي نوع  01-كينوالانترلو  4-:لمتابعة اهمية الانترلوكين هدف الدراسة
 ولإيجاد معدل الحالات المؤكدة في محافظة بابل وللمقارنة بين معدل تلك النسب والاسباب المحتملة للانتقال وطرق الوقاية.
 4-ةكين لمقارنة الانترلو  Cونوع  Bمريض تعاني من التهاب الكبد الفايروسي نوع  81تم اخذ مجموعة مكونة من  المواد وطرق العمل:
شخص والذين لا يعانون من مرض ظاهريا في مختبر الصحة  41وتمت المقارنة مع مجموعة السيطرة المكونة من  01-والانترلوكين 
 بابل/العامة
نالك زيادة هفي كلا المجموعتين بالمقارنة الى مجموعة السيطرة بينما كان  4-وي كبير في الانترلوكين اظهرت النتائج نقص معن النتائج:
 معنوية كبيرة في كلا المجموعتين بالمقارنة مع مجموعة السيطرة. 
 الاستنتاج:
ي غير كمعيار مختبر  4-نترلوكين. ومن الممكن استخدام الاCو نوع  Bالعوامل المناعية تكون ضرورية جدافي مصير التهاب الكبد نوع 
بسبب  Cع و نو  Bمن الممكن ان يزيد  الاصابة  بالتهاب الكبد نوع  01-مباشر لتقييم ضرر الكبد بدلا من الفحص النسيجي. الانترلوكين 
لمتسبب ب ا Cو نوع  B من الممكن ان يزيد من  التهاب الكبد نوع  4Gدوره كعامل مضاد للعوامل الالتهابية. وكذلك الاميونوكلوبين نوع 
 .01-الانترلوكين
 01-, الانترلوكين4-, الانترلوكين  C و نوع Bالتهاب الكبد نوع  الدالة:الكلمات 
 
